The pharmaceutical giant argues waiving intellectual property protections could see scarce inputs snapped up making it harder to produce vaccines
- Full Story podcast: Is Australia stopping the world’s poorest nations from accessing cheap vaccines?
- What is patent waiving and will it solve the global shortage?
Pfizer has warned Australia against joining a growing push to waive the intellectual property protections for Covid-19 vaccines, arguing it could actually harm vaccine supply and invite less safe copycats.
Pfizer Australia made the submission to a parliamentary inquiry into vaccine fraud, arguing that open-slather production could see scarce inputs snapped up making it harder to produce its vaccines, which form a large component of Australia’s rollout.
Australia has been engaging constructively to find a proposed solution to the #TRIPSwaiver. We look forward to continuing to work with the US and others to find solutions that facilitate access to Covid-19 vaccines. https://t.co/imRlkNtPFV
Related: Is Australia stopping the world’s poorest nations from accessing cheap Covid-19 vaccines?
